Cyclosporine-Iinduced Glycosuria

• Published in: Skinmed Vol. 22; no. 5; p. 382
• Main Authors: Wei, Heng Li, Madeline, Ho Sheun Ling, Weng, Yew Yik
• Format: Journal Article
• Language: English
• Published: United States 2024
• Subjects: Adalimumab - administration & dosage; Adalimumab - adverse effects; Adalimumab - therapeutic use; Adult; Cyclosporine - administration & dosage; Cyclosporine - therapeutic use; Glycosuria - chemically induced; Humans; Immunosuppressive Agents - administration & dosage; Immunosuppressive Agents - adverse effects; Immunosuppressive Agents - therapeutic use; Male; Psoriasis - drug therapy

Our first patient was a 42-year-old healthy Chinese man with moderately severe psoriasis, not adequately controlled with potent topical steroids and vitamin D analogs. His pre-immunosuppressant work-up was normal. He was prescribed methotrexate prior to switching to cyclosporine with an initial dose of 200 mg daily (2.44 mg/kg/day). His urinalysis was normal 2 months after initiating cyclosporine. After 18 months of cyclosporine therapy, his urinalysis revealed glycosuria (300 mg/dL), even though his fasting serum glucose was 5.2 mmol/L (normal) and there was no indication of any urinary tract infection (UTI). This occurred at a dose of 100 mg every 2 days (0.610 mg/kg/day). The glycosuria resolved on the next check, and he was shifted to adalimumab.